Silver-enhanced in situ hybridization as an alternative to fluorescence in situ hybridization for assaying HER2 amplifcation in clinical breast cancer

Journal of Breast Cancer

Volumn 14, Issue 4, 2011, Pages 276-282

  Park, Kyeongmee ^a   Han, Sehwan ^a   Kim, Jung Yeon ^a   Kim, Hyun Jung ^a   Kwon, Ji Eun ^a   Gwak, Geumhee ^a  

^a Inje University College of Medicine   (South Korea)

Author keywords

Breast neoplasms; HER2; In situ hybridization

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; FEASIBILITY STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; SILVER ENHANCED IN SITU HYBRIDIZATION; TISSUE MICROARRAY;

EID: 84863042768     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2011.14.4.276     Document Type: Article

References (25)

1. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-pos-itive breast cancer. N Engl J Med 2005;353:1673-84.
2. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab afer adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369:29-36.
3. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733-43.
4. Wolf AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45.
5. Penault-Llorca F, Bilous M, Dowsett M, Hanna W, Osamura RY Rüschof J, et al. Emerging technologies for assessing HER2 amplifcation. Am J Clin Pathol 2009;132:539-48.
6. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Horto-bagyi GN. Te HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009; 14: 320-68.
7. Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart MJ, et al. Chromogenic in situ hybridization: a practical alternative for fuorescence in situ hybridization to detect HER-2/neu oncogene amplifcation in archival breast cancer samples. Am J Pathol 2000;157:1467-72.
8. Park K, Kim J, Lim S, Han S, Lee JY. Comparing fuorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray. Mod Pathol 2003;16:937-43.
9. Laakso M, Tanner M, Isola J. Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplifcation in archival breast tumours. JPathol. 2006;210:3-9.
10. Powell RD, Pettay JD, Powell WC, Roche PC, Grogan TM, Hainfeld JF, et al. Metallographic in situ hybridization. Hum Pathol 2007;38:1145-59.
11. Kang J, Kwon GY Lee YH, Gong G Comparison of silver-enhanced in situ hybridization and fuorescence in situ hybridization for HER2 gene status in breast carcinomas. J Breast Cancer 2009; 12:235-40.
12. Kim TJ, Kim TE, Jung ES, Yim HW, Song BJ, Jung SS, et al. Te comparison of automated silver in situ hybridization and fuorescence in situ hybridization for evaluating HER2 gene amplifcation in breast carcinoma. J Breast Cancer 2009;12:295-301.
13. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. Te value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
14. Dietel M, Ellis IO, Höfer H, Kreipe H, Moch H, Dankof A, et al. Comparison of automated silver enhanced in situ hybridization (SISH) and fuorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch 2007;451:19-25.
15. Papouchado BG, Myles J, Lloyd RV Stoler M, Oliveira AM, Downs-Kelly E, et al. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility. Am J Surg Pathol 2010;34:767-76.
16. Grimm EE, Schmidt RA, Swanson PE, Dintzis SM, Allison KH. Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases. Am J Clin Pathol 2010;134:284-92.
17. Ross JS. Human epidermal growth factor receptor 2 testing in 2010: does chromosome 17 centromere copy number make any diference? J Clin Oncol 2010;28:4293-5.
18. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab afer adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
19. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-pos-itive breast cancer. N Engl J Med 2005;353:1673-84.
20. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab afer adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36.
21. Shimizu C, Fukutomi T, Tsuda H, Akashi-Tanaka S, Watanabe T, Nana-sawa T, et al. c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. J Surg Oncol 2000;73:17-20.
22. Tanner M, Järvinen P, Isola J. Amplifcation of HER-2/neu and topoi-somerase IIalpha in primary and metastatic breast cancer. Cancer Res 2001;61:5345-8.
23. Santinelli A, Pisa E, Stramazzotti D, Fabris G. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy Int J Cancer 2008;122:999-1004.
24. Lower EE, Glass E, Blau R, Harman S. HER-2/neu expression in primary andmetastatic breast cancer. Breast Cancer Res Treat 2009; 113:301-6.
25. Park K, Han S, Kim HJ, Kim J, Shin E. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fuorescence in situ hybridization and immunohistochemistry. Histopathology 2006;48:702-7.